News & events

Join us for an upcoming webinar on neutrophil activity, with a special focus on inflammatory bowel diseases!

On June 13, 2023 (11:00-12:30 EST), the ECM Pharmacology Symposium Series continues in close collaboration with our partner, the ECM Pharmacology Congress.

Join us for an engaging webinar focused on the intriguing interplay between inflammatory bowel diseases (IBD) and neutrophil activity, with a special emphasis on the insights provided by the unique CPa9-HNE serum calprotectin.

Our experts will unravel the biological processes of mucosal damage and healing in inflammatory bowel disease (IBD), and how it relates to neutrophil activity and the extracellular matrix (ECM). Specifically, we will delve into the role of mucosal damage, intestinal fibrosis, and fibro-inflammation, and how they impact ECM remodeling and integrity.

Preliminary Agenda

11:00 - 11:30 The role of neutrophil activity in tissue destruction - Dr. Morten A. Karsdal

11:30 - 11:50 Mucosal damage and intestinal fibrosis in IBD - Dr. Florian Rieder

11:50 - 12:10 Fibro-inflammation in IBD a new frontier and how to quantify it - Dr. Joachim Høg Mortensen

12:10 - 12:30 Questions from the chat

All times in EDT.

Sign up today!

Speaker line-up

Florian Rieder, MD

• Dr. Rieder's clinical focus is patients with IBD with a special emphasis on the field of pathogenesis, prediction, and therapy of intestinal fibrosis.
• Dr. Rieder has published over 150 articles (h-index 52) and book chapters and he has been awarded the Sherman Emerging Leaders award.
• He is the lead author of the ECCO guidelines on Ulcerative colitis and the first ECCO clinical consensus on 'Diagnosis and Management of Intestinal Fibrosis'. He is a past associate editor of Clinical and Translational Gastroenterology.
• Dr. Rieder serves as an abstract reviewer for all major GI conferences and on several editorial boards of medical journals. 
• Dr. Rieder has significant ties to the ECCO, having served as the chair of Y-ECCO, a member of the ECCO operational board, a prior Y-ECCO committee member, and a member of the scientific committee.
• He was the past chair of REACH-IBD and is currently the Co-Chair of the Professional Education Committee of the Crohn’s and Colitis Foundation.
• Dr. Rieder is the leading Principal Investigator (PI) of the international Stenosis Therapy and Research (STAR) Consortium, which aims to test anti-fibrotic medications in stricturing Crohn’s disease.

Dr. Morten A. Karsdal

• Dr. Karsdal joined Nordic Bioscience in 2001 and became CEO in 2010 and currently serves as the Chairman of the Extracellular Matrix Pharmacology Congress.
• Dr. Karsdal is recognized for his expertise in the extracellular matrix and disease biology, and a strong commitment to biomarker development.
• He has published over 600 peer-reviewed articles and has presented at numerous international scientific conferences.
• Dr. Karsdal has an h-index of 89 and has been cited more than 30.000 times.

Dr. Joachim Høg Mortensen

• Dr. Mortensen joined Nordic Bioscience in 2013 and currently serves as Head of Department of Gastrointestinal Diseases.
• The group's research activities span from biomarker discovery to preclinical and clinical trial exploration focusing on the development and validation of blood-based biomarkers to quantify fibro-inflammation which covers neutrophil activity, mucosal damage and intestinal fibrosis in serum of patients with gastrointestinal diseases e.g. inflammatory bowel disease.
• The group's primary focus is to evaluate pharmacodynamics changes, efficacy and monitoring of response to various treatments using biomarkers reflecting fibro-inflammation.
• Biomarkers are developed to support and understand fibro-inflammation-associated IBD disease progression and response to treatment, where the biomarkers are applied from target selection to clinical trial monitoring.

Scientific topics

In this edition of the ECM Pharmacology Symposium Series, we will address the mechanisms of neutrophil activity in chronic diseases, in particular on fibro-inflammation in inflammatory bowel diseases, focusing in particular on fibro-inflammation and mucosal damage.

We will also present the latest methods for quantifying fibro-inflammation in IBD, such as the novel serum calprotectin biomarker CPa9-HNE, and discuss the implications of these findings for patients. In addition, we will look at current and future treatment options for IBD and the potential impact of these advances on patient outcomes.

This webinar is an excellent opportunity for researchers, clinicians, and healthcare professionals to gain valuable insight into the latest developments in IBD research and treatment, and to gain a deeper understanding of the intricate interplay of neutrophil activity, mucosal damage and fibro-inflammation in IBD.

Sign up today!